Tedizolid Neuropathies

Civil Hospices of Lyon

Status: Completed

Conditions: While Receiving Tedizolid Therapy Between July 2019 and December 2024; Adult Patients Developing Optic or Peripheral Neuropathy

Treatments: Other: Determine patient demographic and clinical characteristics at baseline

Study type: Observational

Funder types: Other

Identifiers

NCT07143240

25-5138

Details and patient eligibility

About

Tedizolid is a new oxazolidinone, related to linezolid. It has obtained marketing authorization for the treatment of skin and soft tissue infections. Its potential interest compared to linezolid lies mainly in its better tolerance in the context of more prolonged treatments required in chronic Gram-positive cocci infections such as osteoarticular infections. Indeed, linezolid has hematological toxicity, appearing beyond 10 days of treatment. Due to a lower dosage and lower mitochondrial toxicity, the hematological tolerance of tedizolid is better, even allowing it to be used as a relay from linezolid after the occurrence of hematotoxicity. Another side effect of the oxazolidinone class is the occurrence of optic and peripheral neuropathies observed under linezolid. The pharmacological properties of tedizolid and in vitro and in vivo data suggested a lower risk of neurotoxicity, although a few cases have been published..

Enrollment: 5 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years
• Patients developing optic or peripheral neuropathy while receiving tedizolid therapy

Exclusion criteria

• 18 years

Trial design

5 participants in 1 patient group

Adult patients developing optic or peripheral neuropathy while receiving tedizolid therapy

Description:

The study population included subjects aged ≥ 18 years who received tedizolid for infections between July 2019 and December 2024. Subjects younger than 18 years old were excluded.

Treatment:

Other: Determine patient demographic and clinical characteristics at baseline